Companies: 10,795·Total market cap: $144.5T
Oculis Holding AG

Oculis Holding AG

OCSNASDAQHealthcare● Active
$10.71
$-0.50(-4.46%)
Market Cap$612285345
P/E Ratio
52W High$34.475
52W Low$10.52
Overview

Oculis Holding AG (OCS) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

ocs · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Oculis Holding AG (OCS) measures how much investors pay for each dollar of the company's trailing earnings. OCS's current PE ratio of N/A is calculated by dividing its stock price of $10.71 by its TTM earnings per share of -$1.61.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-1.73
Based on 7 analysts
EPS (TTM)
-$1.61
TTM · diluted EPS
PEG Ratio
-0.16
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Oculis Holding AG SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2020 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Oculis Holding AG
Oculis Holding AGYou
OCS
$612MN/A-$1.61
AnaptysBio, Inc.
AnaptysBio, Inc.
ANAB
$2.2BN/A-$0.48
BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc.
BBOT
$623MN/A-$4.30
Kodiak Sciences Inc.
Kodiak Sciences Inc.
KOD
$1.6BN/A-$4.32
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc.
MNMD
$1.6BN/A-$2.06
Nektar Therapeutics
Nektar Therapeutics
NKTR
$1.1BN/A-$9.73
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
NRIX
$1.4BN/A-$3.05

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 6 of 6 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-1.81
2024-12-31
FY2024
$-2.12
2023-12-31
FY2023
$-2.97
2022-12-31
FY2022
$-1.18
2021-12-31
FY2021
$-0.57
2020-12-31
FY2020
$-0.45

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Oculis Holding AG (OCS) measures how much investors pay for each dollar of the company's trailing earnings. OCS's current PE ratio of N/A is calculated by dividing its stock price of $10.71 by its TTM earnings per share of -$1.61.

PE Ratio = Stock Price ÷ EPS (TTM)
= $10.71 ÷ -$1.61 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

OCS pe ratio · 6 questions

OCS's current PE ratio is N/A as of 2026-06-08, based on a stock price of $10.71 and TTM EPS of -$1.61. Data sourced from Financial Modeling Prep via OCS's SEC 10-K and 10-Q filings.

OCS PE ratioWhat is OCS PE ratioCurrent PE ratio of OCSOCS PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Oculis Holding AG SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08